Presearch is a decentralized search engine, powered by the community.

Oncology / Hematology Approvalls

For decades, the management of patients with advanced prostate cancer has been hormonal therapy, known as androgen deprivation therapy, which is intended to lower testosterone levels. Further incremental progress in the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC) has c …

NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.

If you have metastatic castration-resistant prostate cancer, the hormone therapy you’ve been taking is no longer controlling the disease. Here’s what you should know.

Presearch is a decentralized search engine, powered by the community.

Associate professor of medicine in the Department of Medical Oncology & Therapeutics Research, Tanya Dorff, M.D., is leading a Phase 1 clinical trial that is studying chimeric antigen receptor (CAR) T cells with specificity to prostate stem cell antigen positive (PSCA+) mCRPC.

Prostate cancer is the most common cancer among men worldwide. However, current treatments for prostate cancer patients in advanced stage often fail because of relapse. Prostate cancer stem cells (PCSCs) are resistant to most standard therapies, and are considered to be a major mechanism of cancer metastasis and recurrence. In this review, we summarized current understanding of PCSCs and their self-renewal signaling pathways with a specific focus on Wnt signaling. Although multiple Wnt inhibitors have been developed to target PCSCs, their application is still limited by inefficient delivery and toxicity in vivo. Recently, nanotechnology has opened a new avenue for cancer drug delivery, which significantly increases specificity and reduces toxicity. These nanotechnology-based drug delivery methods showed great potential in targeting PCSCs. Here, we summarized current advancement of nanotechnology-based therapeutic strategies for targeting PCSCs and highlighted the challenges and perspectives in designing future therapies to eliminate PCSCs.

Research in the last decade has clearly revealed a critical role of prostate cancer stem cells (PCSCs) in prostate cancer (PC). Prostate stem cells (PSCs) reside in both basal and luminal layers, and are the target cells of oncogenic transformation, suggesting ...

Background Autologous cellular immunotherapy or immune enhancement therapy has demonstrated some promising benefits for prostate cancer. T cell-based immunotherapy or sipuleucel-T therapy has yielded certain beneficial responses and a slight improvement on the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) as shown in some clinical trials, suggesting that prostate cancer is immunoresponsive. Methods In this study, we developed an adaptive cytokine-induced killer cell (CIK)-based immunotherapeutic application targeting the prostate cancer stem-like cells (PCSCs). In this therapeutic platform, dendritic cells (DC) were isolated from the peripheral blood mononuclear cells (PBMCs) and preloaded or sensitized with immunogenic peptides derived from two PCSC-associated cell membrane molecules, CD44 and EpCAM, followed by co-culture with the expanded peripheral blood lymphocyte (PBL)-derived CIK cells. The in vitro cytotoxic activity of DC-activated CIK cells against PCSCs was determined by CCK8 and TUNEL assays, and the in vivo anti-tumor effect of DC-activated CIK cells on prostate cancer xenograft tumors was evaluated in subcutaneous and orthotopic xenograft models. Results Our results showed that the peptide-sensitized DC-CIK cell preparation manifested significant in vitro cytotoxic activity against the PCSC-enriched prostatospheroids and also in vivo anti-tumor effect against prostate cancer xenografts derived from the PCSC-enriched prostatospheroids. Conclusions Together, our established immunogenic peptide-sensitized DC-CIK-based cell preparation platform manifests its potential immunotherapeutic application in targeting the PCSCs and also prostate cancer.

Stem Cell Cellular Therapy for Prostate Cancer Patients (Immunotherapy) Cellular therapy for prostate cancer patients also known as immunotherapy*, is a natural autologous cellular treatment that employs the use of dendritic cells, natural killer cells (NK cells), and lymphokine-activated killer cells (LAK cells) to suppress

This month is the 40th anniversary of the first unequivocal report in humans that T cells have the power to cure cancer. We look at one study's past, and continued, impact.

Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.

The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

Stem cell transplant replaces a person’s blood-forming (hematopoietic) stem cells. It is used when stem cells or the bone marrow has been damaged by chemotherapy drugs, radiation therapy or disease (such as cancer). The new stem cells make healthy blood cells.

A stem cell transplant (also known as a bone marrow transplant) is a procedure in which defective or cancerous bone marrow is replaced with new, healthy bone marrow cells. A stem cell transplant may be used to treat leukemia and lymphoma, cancers that affect the blood and lymphatic system.

In this article, Sino Biological discusses how stem cells can be used to support and aid cancer therapy and treatment. They discuss different types of stem cells, pathways to target and how to best produce them.

A new study shows how iPS cell technology can produce some of the most potent anti-cancer immune cells for adoptive cell therapies.

Harnessing the immune system to target cancer is the goal of a groundbreaking area of oncology research called cell therapy. And Johnson & Johnson is hard at work in the cutting-edge field, aiming to deliver potential new treatment options to people around the world.

Adoptive cell therapy is a type of cancer treatment that reactivates, enhances, and expands naturally occurring, cancer-fighting immune cells before re-infusing them into patients.

A clinical trial run by UCLA is testing a potentially pioneering form of immunotherapy that could turn a patient's own body into a powerful weapon against cancer.

Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s 2nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem cells” as targets and therapeutic platforms based on stem cells.

In an autologous transplant, your own blood-forming stem cells are collected and stored and then given back to you after treatment to kill the cancer. Learn about how this process works.